Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ropinirole Clear all
Completed Phase 3 Interventional

A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)

NCT00225862
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
37
States / cities
Alabaster, Alabama • Jasper, Alabama • Peoria, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

NCT00314860
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ropinirole 0.25 mg Tablets Under Fasting Conditions

NCT00829504
View directory record Official record
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

NCT00242008
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

NCT00632736
View directory record Official record
Conditions
Parkinson Disease, Parkinson's Disease
Interventions
Ropinirole XL (formerly CR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Not listed Phase 3 Interventional

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

NCT00260793
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ropinirole Hydrochloride
Drug
Lead sponsor
Agarwal, Pinky, M.D.
Individual
Eligibility
25 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 3, 2006 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Remediation for Cocaine Dependence

NCT01393457
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275
View directory record Official record
Conditions
Parkinson Disease
Interventions
Requip PR, Mirapex
Drug
Lead sponsor
Rajesh Pahwa, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

NCT00355641
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
59
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

NCT01494532
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 4 Interventional

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

NCT00334048
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Ropinirole (Requip)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 19, 2026, 7:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

NCT03250117
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole oral product, Ropinirole Implant
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Not applicable Interventional

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

NCT00285727
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Ropinirole CR
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 19, 2026, 7:49 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

NCT01485172
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole monotherapy, placebo monotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

Impact of Switching to Continuous Release Dopamine Agonists

NCT00465452
View directory record Official record
Conditions
Parkinson Disease
Interventions
Continuous Release Dopamine Agonists
Drug
Lead sponsor
University of Toledo
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 2 Interventional

Trial of Ropinirole in Motor Recovery After Stroke

NCT00221390
View directory record Official record
Conditions
Cerebrovascular Accident, Hemiparesis
Interventions
Ropinirole (+ physical therapy), (vs.) Placebo + physical therapy
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

NCT00650104
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole XL (formerly CR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions

NCT00830219
View directory record Official record
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 19, 2026, 7:49 PM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 19, 2026, 7:49 PM EDT